|Ms. Mina Patel Sooch M.B.A., MBA||Founder, CEO, Pres, Treasurer & Vice Chair of the Board||112.79k||N/A||1968|
|Ms. Amy Zaremba Rabourn C.P.A., MAcc, CPA||VP of Fin. & Principal Accounting Officer||53.03k||N/A||1980|
|Mr. Bernhard Hoffmann M.B.A.||VP of Corp. Devel. & Operations and Sec.||45.01k||N/A||1956|
|Dr. Daniela Oniciu Ph.D.||Head of CMC and Global Clinical Supply Manufacturing||N/A||N/A||N/A|
|Dr. Mitchell Brigell||Head of Clinical Devel. & Strategy||N/A||N/A||N/A|
|Ms. Drey Coleman||Head of Clinical Operations||N/A||N/A||N/A|
|Mr. Erik Sims||Director & Corp. Controller||N/A||N/A||N/A|
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Ocuphire Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.